EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of a Commercial PRRSV Vaccine on NADC34-Like PRRSV Challenge

Lili Yuan, Zhenbang Zhu, Juan Fan, Qun Li, Panrao Liu, Xiangdong Li iD

Transboundary and Emerging Diseases · 29.06.2023 · 2023 · 1-5

DOI: 10.1155/2023/4509261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transboundary and Emerging Diseases, erschienen am 29.06.2023. Verfasst von Lili Yuan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzho…. Hauptthemen laut MEDLINE: Porcine Reproductive and Respiratory Syndrome, Porcine respiratory and reproductive syndrome virus, Viral Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Basic Research Program of China, Natural Science Foundation of Jiangsu Province, Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NADC34-like porcine reproductive and respiratory syndrome virus (PRRSV) has become endemic in some provinces of China and caused huge economic losses to local pig industry. The increased reports of NADC34-like PRRSV outbreaks in vaccinated pig herds suggest the limited protection of immunization with commercial vaccines. In this study, we evaluated a commercial PRRSV vaccine that has been widely used in China against the challenge of JS2021NADC34 PRRSV, a highly pathogenic Chinese NADC34-like strain isolated in 2021. The vaccinated pigs developed PRRSV-specific antibody responses, as shown by IDEXX ELISA results. After JS2021NADC34 PRRSV challenge, the vaccinated pigs had low level of viremia but suffered pathological lesions in lungs and lymphoid tissues. The viral antigens were also detected in the above tissues of the vaccinated pigs by immunohistochemistry staining. One out of five pigs in vaccinated group died at 13 days postchallenge. The above results suggested that the commercial PRRSV vaccine could not provide complete protection to the NADC34-like PRRSV infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Porcine Reproductive and Respiratory SyndromePorcine respiratory and reproductive syndrome virusViral VaccinesAnimalsSwineChinaAntibodies, Viral

Substanzen

Viral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, College of Veterinary Medicine, Yangzhou University, Yangzhou, China.
  • Joint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
  • Yangzhou Uni-Bio Pharmaceutical Co., Ltd., Yangzhou, China.

ORCID-Profile: Xiangdong Li

Förderung

  • National Basic Research Program of China
  • Natural Science Foundation of Jiangsu Province
  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Zitieren

APA

Yuan, L., Zhu, Z., Fan, J., Li, Q., Liu, P., & Li, X. (2023). Efficacy of a Commercial PRRSV Vaccine on NADC34-Like PRRSV Challenge. Transboundary and Emerging Diseases, 2023, 1-5. https://doi.org/10.1155/2023/4509261

Vancouver

Yuan L, Zhu Z, Fan J, Li Q, Liu P, Li X. Efficacy of a Commercial PRRSV Vaccine on NADC34-Like PRRSV Challenge. Transboundary and Emerging Diseases. 2023;2023:1-5. doi:10.1155/2023/4509261

BibTeX
@article{Yuan2023,
  author = {Yuan, Lili and Zhu, Zhenbang and Fan, Juan and Li, Qun and Liu, Panrao and Li, Xiangdong},
  title = {Efficacy of a Commercial PRRSV Vaccine on NADC34-Like PRRSV Challenge},
  journal = {Transboundary and Emerging Diseases},
  year = {2023},
  volume = {2023},
  pages = {1--5},
  doi = {10.1155/2023/4509261}
}
Kostenlos starten →